1. Home
  2. CTNM vs BSVN Comparison

CTNM vs BSVN Comparison

Compare CTNM & BSVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • BSVN
  • Stock Information
  • Founded
  • CTNM 2009
  • BSVN 2004
  • Country
  • CTNM United States
  • BSVN United States
  • Employees
  • CTNM N/A
  • BSVN N/A
  • Industry
  • CTNM
  • BSVN Major Banks
  • Sector
  • CTNM
  • BSVN Finance
  • Exchange
  • CTNM Nasdaq
  • BSVN Nasdaq
  • Market Cap
  • CTNM 377.6M
  • BSVN 438.8M
  • IPO Year
  • CTNM 2024
  • BSVN 2018
  • Fundamental
  • Price
  • CTNM $11.28
  • BSVN $44.79
  • Analyst Decision
  • CTNM Strong Buy
  • BSVN Buy
  • Analyst Count
  • CTNM 4
  • BSVN 3
  • Target Price
  • CTNM $29.25
  • BSVN $46.00
  • AVG Volume (30 Days)
  • CTNM 135.4K
  • BSVN 35.1K
  • Earning Date
  • CTNM 02-16-2025
  • BSVN 01-16-2025
  • Dividend Yield
  • CTNM N/A
  • BSVN 2.00%
  • EPS Growth
  • CTNM N/A
  • BSVN 58.69
  • EPS
  • CTNM N/A
  • BSVN 4.84
  • Revenue
  • CTNM N/A
  • BSVN $97,449,000.00
  • Revenue This Year
  • CTNM N/A
  • BSVN N/A
  • Revenue Next Year
  • CTNM N/A
  • BSVN $3.97
  • P/E Ratio
  • CTNM N/A
  • BSVN $9.30
  • Revenue Growth
  • CTNM N/A
  • BSVN 37.95
  • 52 Week Low
  • CTNM $11.38
  • BSVN $24.64
  • 52 Week High
  • CTNM $22.00
  • BSVN $50.26
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • BSVN 49.50
  • Support Level
  • CTNM N/A
  • BSVN $41.50
  • Resistance Level
  • CTNM N/A
  • BSVN $50.26
  • Average True Range (ATR)
  • CTNM 0.00
  • BSVN 1.91
  • MACD
  • CTNM 0.00
  • BSVN 0.03
  • Stochastic Oscillator
  • CTNM 0.00
  • BSVN 37.56

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About BSVN Bank7 Corp. Common stock

Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a wide variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. it offers commercial real estate lending, hospitality lending, energy lending, and commercial and industrial lending, and also provides consumer lending services to individuals.

Share on Social Networks: